HEADER TRANSFERASE 17-FEB-07 2JGZ TITLE CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: RESIDUES 1-288; COMPND 5 SYNONYM: P33 PROTEIN KINASE; COMPND 6 EC: 2.7.1.-; COMPND 7 ENGINEERED: YES; COMPND 8 OTHER_DETAILS: PHOSPHORYLATED ON THR160; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: G2/MITOTIC-SPECIFIC CYCLIN-B1; COMPND 11 CHAIN: B; COMPND 12 FRAGMENT: RESIDUES 167-426; COMPND 13 SYNONYM: CYCLIN B1; COMPND 14 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 9 ORGANISM_COMMON: HUMAN; SOURCE 10 ORGANISM_TAXID: 9606; SOURCE 11 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS PROTEIN KINASE, UBL CONJUGATION, PHOSPHORYLATION, SERINE/THREONINE- KEYWDS 2 PROTEIN KINASE, KINASE, CYCLIN, MITOSIS, CELL CYCLE, TRANSFERASE, KEYWDS 3 ATP-BINDING, POLYMORPHISM, CELL DIVISION, NUCLEOTIDE-BINDING, KEYWDS 4 SUBSTRATE SPECIFICITY EXPDTA X-RAY DIFFRACTION AUTHOR N.R.BROWN,E.PETRI,E.D.LOWE,V.SKAMNAKI,L.N.JOHNSON REVDAT 5 13-DEC-23 2JGZ 1 REMARK REVDAT 4 09-OCT-19 2JGZ 1 JRNL LINK REVDAT 3 24-FEB-09 2JGZ 1 VERSN REVDAT 2 26-JUN-07 2JGZ 1 JRNL REVDAT 1 22-MAY-07 2JGZ 0 JRNL AUTH N.R.BROWN,E.D.LOWE,E.PETRI,V.SKAMNAKI,R.ANTROBUS,L.N.JOHNSON JRNL TITL CYCLIN B AND CYCLIN A CONFER DIFFERENT SUBSTRATE RECOGNITION JRNL TITL 2 PROPERTIES ON CDK2. JRNL REF CELL CYCLE V. 6 1350 2007 JRNL REFN ESSN 1551-4005 JRNL PMID 17495531 JRNL DOI 10.4161/CC.6.11.4278 REMARK 2 REMARK 2 RESOLUTION. 2.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.64 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 3 NUMBER OF REFLECTIONS : 17963 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.208 REMARK 3 R VALUE (WORKING SET) : 0.205 REMARK 3 FREE R VALUE : 0.275 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.200 REMARK 3 FREE R VALUE TEST SET COUNT : 979 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.90 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.98 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1267 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2720 REMARK 3 BIN FREE R VALUE SET COUNT : 74 REMARK 3 BIN FREE R VALUE : 0.3410 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4432 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 5 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 36.82 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.02000 REMARK 3 B22 (A**2) : 0.02000 REMARK 3 B33 (A**2) : -0.03000 REMARK 3 B12 (A**2) : 0.01000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 2.771 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.403 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.294 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 15.137 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.923 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.864 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 4535 ; 0.012 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 6144 ; 1.442 ; 1.974 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 547 ; 6.742 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 199 ;38.234 ;23.819 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 820 ;19.630 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 26 ;20.071 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 694 ; 0.098 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3359 ; 0.004 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 2085 ; 0.231 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 3151 ; 0.316 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 127 ; 0.171 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 35 ; 0.246 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 3 ; 0.180 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 2807 ; 0.682 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 4457 ; 1.228 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1938 ; 1.514 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1687 ; 2.535 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2JGZ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 17-FEB-07. REMARK 100 THE DEPOSITION ID IS D_1290031501. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 6.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID29 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.87260 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19123 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.900 REMARK 200 RESOLUTION RANGE LOW (A) : 30.180 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 8.800 REMARK 200 R MERGE (I) : 0.12000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 16.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.06 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 8.20 REMARK 200 R MERGE FOR SHELL (I) : 0.52000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 1QMZ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 60.50 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.11 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.9-1.2 M AMMONIUM SULPHATE, 100 MM REMARK 280 MES PH 6.0-6.5, 100 MM POTASSIUM CHLORIDE, PH 6.00 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 61 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 -X,-Y,Z+1/2 REMARK 290 5555 Y,-X+Y,Z+5/6 REMARK 290 6555 X-Y,X,Z+1/6 REMARK 290 7555 Y,X,-Z+1/3 REMARK 290 8555 X-Y,-Y,-Z REMARK 290 9555 -X,-X+Y,-Z+2/3 REMARK 290 10555 -Y,-X,-Z+5/6 REMARK 290 11555 -X+Y,Y,-Z+1/2 REMARK 290 12555 X,X-Y,-Z+1/6 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 83.87833 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 167.75667 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 125.81750 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 209.69583 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 41.93917 REMARK 290 SMTRY1 7 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 7 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 83.87833 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 9 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 9 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 9 0.000000 0.000000 -1.000000 167.75667 REMARK 290 SMTRY1 10 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 10 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 10 0.000000 0.000000 -1.000000 209.69583 REMARK 290 SMTRY1 11 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 11 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 11 0.000000 0.000000 -1.000000 125.81750 REMARK 290 SMTRY1 12 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 12 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 12 0.000000 0.000000 -1.000000 41.93917 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OE1 GLU A 57 NH2 ARG A 122 2.02 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 59 97.97 -160.82 REMARK 500 GLU A 73 38.49 -20.71 REMARK 500 ASN A 74 -14.88 -156.14 REMARK 500 SER A 94 36.06 -83.82 REMARK 500 ASP A 127 45.03 -163.75 REMARK 500 ASP A 145 74.66 51.61 REMARK 500 VAL A 164 139.22 66.31 REMARK 500 SER A 181 -153.45 -145.65 REMARK 500 ARG A 199 -17.84 78.21 REMARK 500 TRP A 227 75.84 -150.39 REMARK 500 SER A 239 25.07 -63.93 REMARK 500 ASP A 256 174.96 -58.54 REMARK 500 PHE A 286 39.88 -91.85 REMARK 500 GLN A 287 -88.04 -22.90 REMARK 500 GLN B 185 46.45 -106.06 REMARK 500 ARG B 299 123.33 -38.88 REMARK 500 ILE B 312 79.51 -116.62 REMARK 500 ASP B 335 -3.23 -59.52 REMARK 500 LEU B 356 -155.58 -103.82 REMARK 500 ASP B 357 -81.49 -28.89 REMARK 500 ASN B 358 -20.32 -150.74 REMARK 500 TRP B 361 84.73 -66.59 REMARK 500 LYS B 411 28.49 40.11 REMARK 500 LEU B 415 141.84 -34.13 REMARK 500 PRO B 416 76.25 -63.09 REMARK 500 LEU B 418 66.59 -108.20 REMARK 500 LEU B 422 49.36 -81.74 REMARK 500 VAL B 423 70.80 -109.81 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 THR A 72 GLU A 73 -149.52 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2- ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR REMARK 900 OLOMOUCINE. REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2- REMARK 900 YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1YKR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR REMARK 900 RELATED ID: 2A0C RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9- REMARK 900 TRISUBSTITUTED PURINE CYCLIN -DEPENDENT KINASE INHIBITOR REMARK 900 RELATED ID: 2A4L RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE REMARK 900 DIN-101312 REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 5-BROMO- INDIRUBINE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5T RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE REMARK 900 PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A REMARK 900 PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 REMARK 900 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE REMARK 900 RELATED ID: 2CLX RELATED DB: PDB REMARK 900 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, REMARK 900 CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR REMARK 900 EFFECTS REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D REMARK 900 MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR REMARK 900 RELATED ID: 2IW9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2J9M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC REMARK 900 AMINOPYRIMIDINE REMARK 900 RELATED ID: 2B9R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN B1 REMARK 999 REMARK 999 SEQUENCE REMARK 999 RESIDUE SER 0 DERIVES FROM THE EXPRESSION CONSTRUCT REMARK 999 A FRAGMENT CONTAINING RESIDUES 165-433 WAS USED IN THIS REMARK 999 STUDY DBREF 2JGZ A 0 0 PDB 2JGZ 2JGZ 0 0 DBREF 2JGZ A 1 288 UNP P24941 CDK2_HUMAN 1 288 DBREF 2JGZ B 167 426 UNP P14635 CCNB1_HUMAN 167 426 SEQRES 1 A 289 SER MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU SEQRES 2 A 289 GLY THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU SEQRES 3 A 289 THR GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP SEQRES 4 A 289 THR GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU SEQRES 5 A 289 ILE SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL SEQRES 6 A 289 LYS LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR SEQRES 7 A 289 LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE SEQRES 8 A 289 MET ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU SEQRES 9 A 289 ILE LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA SEQRES 10 A 289 PHE CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS SEQRES 11 A 289 PRO GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS SEQRES 12 A 289 LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO SEQRES 13 A 289 VAL ARG THR TYR TPO HIS GLU VAL VAL THR LEU TRP TYR SEQRES 14 A 289 ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER SEQRES 15 A 289 THR ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA SEQRES 16 A 289 GLU MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER SEQRES 17 A 289 GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY SEQRES 18 A 289 THR PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET SEQRES 19 A 289 PRO ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN SEQRES 20 A 289 ASP PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY SEQRES 21 A 289 ARG SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN SEQRES 22 A 289 LYS ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE SEQRES 23 A 289 PHE GLN ASP SEQRES 1 B 260 CYS SER GLU TYR VAL LYS ASP ILE TYR ALA TYR LEU ARG SEQRES 2 B 260 GLN LEU GLU GLU GLU GLN ALA VAL ARG PRO LYS TYR LEU SEQRES 3 B 260 LEU GLY ARG GLU VAL THR GLY ASN MET ARG ALA ILE LEU SEQRES 4 B 260 ILE ASP TRP LEU VAL GLN VAL GLN MET LYS PHE ARG LEU SEQRES 5 B 260 LEU GLN GLU THR MET TYR MET THR VAL SER ILE ILE ASP SEQRES 6 B 260 ARG PHE MET GLN ASN ASN CYS VAL PRO LYS LYS MET LEU SEQRES 7 B 260 GLN LEU VAL GLY VAL THR ALA MET PHE ILE ALA SER LYS SEQRES 8 B 260 TYR GLU GLU MET TYR PRO PRO GLU ILE GLY ASP PHE ALA SEQRES 9 B 260 PHE VAL THR ASP ASN THR TYR THR LYS HIS GLN ILE ARG SEQRES 10 B 260 GLN MET GLU MET LYS ILE LEU ARG ALA LEU ASN PHE GLY SEQRES 11 B 260 LEU GLY ARG PRO LEU PRO LEU HIS PHE LEU ARG ARG ALA SEQRES 12 B 260 SER LYS ILE GLY GLU VAL ASP VAL GLU GLN HIS THR LEU SEQRES 13 B 260 ALA LYS TYR LEU MET GLU LEU THR MET LEU ASP TYR ASP SEQRES 14 B 260 MET VAL HIS PHE PRO PRO SER GLN ILE ALA ALA GLY ALA SEQRES 15 B 260 PHE CYS LEU ALA LEU LYS ILE LEU ASP ASN GLY GLU TRP SEQRES 16 B 260 THR PRO THR LEU GLN HIS TYR LEU SER TYR THR GLU GLU SEQRES 17 B 260 SER LEU LEU PRO VAL MET GLN HIS LEU ALA LYS ASN VAL SEQRES 18 B 260 VAL MET VAL ASN GLN GLY LEU THR LYS HIS MET THR VAL SEQRES 19 B 260 LYS ASN LYS TYR ALA THR SER LYS HIS ALA LYS ILE SER SEQRES 20 B 260 THR LEU PRO GLN LEU ASN SER ALA LEU VAL GLN ASP LEU MODRES 2JGZ TPO A 160 THR PHOSPHOTHREONINE HET TPO A 160 11 HETNAM TPO PHOSPHOTHREONINE HETSYN TPO PHOSPHONOTHREONINE FORMUL 1 TPO C4 H10 N O6 P FORMUL 3 HOH *5(H2 O) HELIX 1 1 PRO A 45 LEU A 58 1 14 HELIX 2 2 LEU A 87 SER A 94 1 8 HELIX 3 3 PRO A 100 SER A 120 1 21 HELIX 4 4 LYS A 129 GLN A 131 5 3 HELIX 5 5 THR A 165 ARG A 169 5 5 HELIX 6 6 ALA A 170 LEU A 175 1 6 HELIX 7 7 THR A 182 ARG A 199 1 18 HELIX 8 8 SER A 207 GLY A 220 1 14 HELIX 9 9 GLY A 229 MET A 233 5 5 HELIX 10 10 ASP A 247 VAL A 252 1 6 HELIX 11 11 ASP A 256 MET A 266 1 11 HELIX 12 12 SER A 276 LEU A 281 1 6 HELIX 13 13 ALA A 282 GLN A 287 5 6 HELIX 14 14 TYR B 170 GLN B 185 1 16 HELIX 15 15 THR B 198 ARG B 217 1 20 HELIX 16 16 LEU B 219 GLN B 235 1 17 HELIX 17 17 PRO B 240 LYS B 242 5 3 HELIX 18 18 MET B 243 GLU B 260 1 18 HELIX 19 19 GLU B 265 THR B 273 1 9 HELIX 20 20 THR B 278 ASN B 294 1 17 HELIX 21 21 LEU B 301 ILE B 312 1 12 HELIX 22 22 ASP B 316 MET B 331 1 16 HELIX 23 23 LEU B 332 VAL B 337 5 6 HELIX 24 24 PRO B 340 LEU B 356 1 17 HELIX 25 25 THR B 362 LEU B 369 1 8 HELIX 26 26 THR B 372 GLN B 392 1 21 HELIX 27 27 MET B 398 TYR B 404 1 7 HELIX 28 28 THR B 406 ALA B 410 5 5 HELIX 29 29 LYS B 411 LEU B 415 5 5 SHEET 1 AA 5 PHE A 4 GLU A 12 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 THR A 72 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 LINK C TYR A 159 N TPO A 160 1555 1555 1.32 LINK C TPO A 160 N HIS A 161 1555 1555 1.33 CISPEP 1 VAL A 154 PRO A 155 0 7.59 CISPEP 2 ILE B 312 GLY B 313 0 -3.48 CISPEP 3 GLY B 313 GLU B 314 0 -3.26 CISPEP 4 ASP B 357 ASN B 358 0 -14.05 CISPEP 5 ASP B 425 LEU B 426 0 -12.31 CRYST1 104.780 104.780 251.635 90.00 90.00 120.00 P 61 2 2 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.009544 0.005510 0.000000 0.00000 SCALE2 0.000000 0.011020 0.000000 0.00000 SCALE3 0.000000 0.000000 0.003974 0.00000